Sickle Cell Anemia Clinical Trial
Official title:
Potential Role of Gum Arabic as Fetal Hemoglobin Agent in Sudanese Sickle Cell Anemia Patients
Verified date | June 2015 |
Source | Al-Neelain University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether Gum Arabic is effective as fetal hemoglobin inducing agent for sickle cell anemia patients.
Status | Completed |
Enrollment | 47 |
Est. completion date | January 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. over 5 year old 2. less t5han 50 3. diagnosed with homozygous sickle cell anemia by Hb electrophoresis Exclusion Criteria: 1. patients received blood transfusion within the last three months or admitted to the hospital within 2 weeks because of Sickle cell anemia -related events or crisis. |
Country | Name | City | State |
---|---|---|---|
Sudan | Military Hospital | Omdurman | Khartoum |
Lead Sponsor | Collaborator |
---|---|
Al-Neelain University | Military hospital, Ministry of Higher Education and Scientific Research, Republic of Sudan |
Sudan,
Ballal A, Bobbala D, Qadri SM, Föller M, Kempe D, Nasir O, Saeed A, Lang F. Anti-malarial effect of gum arabic. Malar J. 2011 May 20;10:139. doi: 10.1186/1475-2875-10-139. — View Citation
Fathallah H, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006:58-62. Review. — View Citation
Kutlar A, Reid ME, Inati A, Taher AT, Abboud MR, El-Beshlawy A, Buchanan GR, Smith H, Ataga KI, Perrine SP, Ghalie RG. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013 Nov;88(11):E255-60. doi: 10.1002/ajh.23533. Epub 2013 Oct 3. — View Citation
Matsumoto N, Riley S, Fraser D, Al-Assaf S, Ishimura E, Wolever T, Phillips GO, Phillips AO. Butyrate modulates TGF-beta1 generation and function: potential renal benefit for Acacia(sen) SUPERGUM (gum arabic)? Kidney Int. 2006 Jan;69(2):257-65. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint of the study will be the level of fetal hemoglobin after three months | fetal hemoglobin will be measured each month for three months | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04581356 -
Voxelotor Sickle Cell Exercise Study
|
Phase 4 | |
Completed |
NCT02712346 -
The Role of Endothelin-1 in Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT01976416 -
Novel Use Of Hydroxyurea in an African Region With Malaria
|
Phase 3 | |
Withdrawn |
NCT02162225 -
Study of Beet Juice for Patients With Sickle Cell Anemia
|
Phase 2 | |
Completed |
NCT01137721 -
State Of The Art Functional Imaging In Sickle Cell Disease
|
||
Terminated |
NCT01350232 -
Treatment of Sickle Cell Anemia With Stem Cell Transplant
|
N/A | |
Withdrawn |
NCT00937144 -
Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil
|
Phase 4 | |
Completed |
NCT00512564 -
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Completed |
NCT00512226 -
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Completed |
NCT00004143 -
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
|
Phase 2 | |
Completed |
NCT00004412 -
Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
|
Phase 2 | |
Withdrawn |
NCT01925001 -
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
|
Phase 2 | |
Completed |
NCT01783990 -
Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol
|
||
Completed |
NCT01848691 -
Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis
|
N/A | |
Completed |
NCT01000155 -
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
|
Phase 2 | |
Completed |
NCT00874172 -
Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy
|
N/A | |
Completed |
NCT00236093 -
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
|
Phase 2 | |
Completed |
NCT00399074 -
Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia
|
Phase 3 | |
Completed |
NCT00004492 -
Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia
|
Phase 1/Phase 2 |